Pharmacogenomic approaches for tailored anti-leukemic therapy in children

Current Medicinal Chemistry

Volumn 20, Issue 17, 2013, Pages 2237-2253

  Stocco, G ^a   Franca, R ^b   Verzegnassi, F ^b   Londero, M ^a,c   Rabusin, M ^b   Decorti, G ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c Sant'Antonio General Hospital   (Italy)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Pharmacogenetics

Indexed keywords

ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; GENETIC VARIABILITY; HUMAN; PEDIATRICS; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

6-MERCAPTOPURINE; ALKALOIDS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHILD; GLUCOCORTICOIDS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; METHOTREXATE; NUCLEOTIDES; PHARMACOGENETICS; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; THIOGUANINE; VINCRISTINE;

EID: 84877931372     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320170008     Document Type: Article

References (143)

1. Pui, C.H.; Evans, W.E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med., 2006, 354, 166-178. (Pubitemid 43076714)
2. Paugh, S.W.; Stocco, G.; Evans, W.E. Pharmacogenomics in pediatric leukemia. Curr. Opin. Pediatr., 2010, 22, 703-710.
3. Zaza, G.; Cheok, M.; Krynetskaia, N.; Thorn, C.; Stocco, G.; Hebert, J.M.; McLeod, H.; Weinshilboum, R.M.; Relling, M.V.; Evans, W.E.; Klein, T.E.; Altman, R.B. Thiopurine pathway. Pharmacogenet. Genomics, 2009, 20, 573-574.
4. Relling, M.V.; Gardner, E.E.; Sandborn, W.J.; Schmiegelow, K.; Pui, C.H.; Yee, S.W.; Stein, C.M.; Carrillo, M.; Evans, W.E.; Klein, T.E. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopu rine dosing. Clin. Pharmacol. Ther., 2011, 89, 387-391.
5. Frandsen, T.L.; Abrahamsson, J.; Lausen, B.; Vettenranta, K.; Heyman, M.; Behrentz, M.; Castor, A.; Wehner, P.S.; Frost, B.M.; Andersen, E.W.; Schmiegelow, K. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lympho blastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. Br. J. Haematol., 2011, 155, 244-247.
6. Relling, M.V.; Hancock, M.L.; Boyett, J.M.; Pui, C.H.; Evans, W.E. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood, 1999, 93, 2817-2823. (Pubitemid 29200771)
7. Stork, L.C.; Matloub, Y.; Broxson, E.; La, M.; Yanofsky, R.; Sather, H.; Hutchinson, R.; Heerema, N.A.; Sorrell, A.D.; Master son, M.; Bleyer, A.; Gaynon, P.S. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: Report of the Children's Oncology Group CCG-1952 clinical trial. Blood, 2010, 115, 2740-2748.
8. Lennard, L.; Richards, S.; Cartwright, C.S.; Mitchell, C.; Lilleyman, J.S.; Vora, A. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related venoocclusive disease of the liver in children with acute lymphoblastic leukemia. Clin. Pharmacol. Ther., 2006, 80, 375-383. (Pubitemid 44479753)
9. Oancea, I.; Png, C.W.; Das, I.; Lourie, R.; Winkler, I.G.; Eri, R.; Subramaniam, N.; Jinnah, H.A.; McWhinney, B.C.; Levesque, J.P.; McGuckin, M.A.; Duley, J.A.; Florin, T.H. A novel mouse model of veno-occlusive disease provides strategies to prevent thiogua nine-induced hepatic toxicity. Gut, 2012, 3, 62, 594-605.
10. Relling, M.V.; Hancock, M.L.; Rivera, G.K.; Sandlund, J.T.; Ribeiro, R.C.; Krynetski, E.Y.; Pui, C.H.; Evans, W.E. Mercapto purine therapy intolerance and heterozygosity at the thiopurine Smethyltransferase gene locus. J. Natl. Cancer Inst., 1999, 91, 2001-2008.
11. Stocco, G.; Crews, K.R.; Evans, W.E. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin. Drug Saf., 2010, 9, 23-37.
12. Stocco, G.; Cheok, M.H.; Crews, K.R.; Dervieux, T.; French, D.; Pei, D.; Yang, W.; Cheng, C.; Pui, C.H.; Relling, M.V.; Evans, W.E. Genetic polymorphism of inosine triphosphate pyrophos phatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther., 2009, 85, 164-172.
13. Paugh, S.W.; Stocco, G.; McCorkle, J.R.; Diouf, B.; Crews, K.R.; Evans, W.E. Cancer pharmacogenomics. Clin. Pharmacol. Ther., 2011, 90, 461-466.
14. Adam de Beaumais, T.; Dervieux, T.; Fakhoury, M.; Medard, Y.; Azougagh, S.; Zhang, D.; Yakouben, K.; Jacqz-Aigrain, E. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lympho blastic leukemia. Cancer Chemother. Pharmacol., 2010, 66, 653-658.
15. Marsh, S.; Van Booven, D.J. The increasing complexity of mercaptopurine pharmacogenomics. Clin. Pharmacol. Ther., 2009, 85, 139-141.
16. Dorababu, P.; Nagesh, N.; Linga, V.G.; Gundeti, S.; Kutala, V.K.; Reddanna, P.; Digumarti, R. Epistatic interactions between thiopu rine methyltransferase (TPMT) and inosine triphosphate pyrophos phatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. Eur. J. Clin. Pharmacol., 2012, 68, 379-387.
17. Dorababu, P.; Naushad, S.M.; Linga, V.G.; Gundeti, S.; Nagesh, N.; Kutala, V.K.; Reddanna, P.; Digumarti, R. Genetic variants of thiopurine and folate metabolic pathways determine 6-MPmediated hematological toxicity in childhood ALL. Pharmaco genomics, 2012, 13, 1001-1008.
18. Kim, H.; Kang, H.J.; Kim, H.J.; Jang, M.K.; Kim, N.H.; Oh, Y.; Han, B.D.; Choi, J.Y.; Kim, C.W.; Lee, J.W.; Park, K.D.; Shin, H.Y.; Ahn, H.S. Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism. PLoS One, 2012, 7, e45558.
19. Tanaka, Y.; Manabe, A.; Nakadate, H.; Kondoh, K.; Nakamura, K.; Koh, K.; Utano, T.; Kikuchi, A.; Komiyama, T. The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children. Leuk. Res., 2012, 36, 560-564.
20. Stocco, G.; Franca, R.; Verzegnassi, F.; Londero, M.; Rabusin, M.; Decorti, G. Multilocus genotypes of relevance for drug metabo lizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia. Front. Genet., 2013, 2, 3, 309.
21. Trevino, L.R.; Shimasaki, N.; Yang, W.; Panetta, J.C.; Cheng, C.; Pei, D.; Chan, D.; Sparreboom, A.; Giacomini, K.M.; Pui, C.H.; Evans, W.E.; Relling, M.V. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol., 2009, 27, 5972-5978.
22. Stocco, G.; Yang, W.; Crews, K.R.; Thierfelder, W.E.; Decorti, G.; Londero, M.; Franca, R.; Rabusin, M.; Valsecchi, M.G.; Pei, D.; Cheng, C.; Paugh, S.W.; Ramsey, L.B.; Diouf, B.; McCorkle, J.R.; Jones, T.S.; Pui, C.H.; Relling, M.V.; Evans, W.E. PACSIN2 polymorphism influences TPMT activity and mercaptopurinerelated gastrointestinal toxicity. Hum. Mol. Genet., 2012, 21, 4793-4804.
23. Li, F.; Fridley, B.L.; Matimba, A.; Kalari, K.R.; Pelleymounter, L.; Moon, I.; Ji, Y.; Jenkins, G.D.; Batzler, A.; Wang, L.; Weinshil boum, R.M. Ecto-5'-nucleotidase and thiopurine cellular circulation: Association with cytotoxicity. Drug Metab. Dispos., 2010, 38, 2329-2338.
24. Mikkelsen, T.S.; Thorn, C.F.; Yang, J.J.; Ulrich, C.M.; French, D.; Zaza, G.; Dunnenberger, H.M.; Marsh, S.; McLeod, H.L.; Giacomini, K.; Becker, M.L.; Gaedigk, R.; Leeder, J.S.; Kager, L.; Relling, M.V.; Evans, W.; Klein, T.E.; Altman, R.B. PharmGKB summary: Methotrexate pathway. Pharmacogenet. Genomics, 2011, 21, 679-686.
25. Stark, M.; Wichman, C.; Avivi, I.; Assaraf, Y.G. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood, 2009, 113, 4362-4369.
26. Cheng, Q.; Cheng, C.; Crews, K.R.; Ribeiro, R.C.; Pui, C.H.; Relling, M.V.; Evans, W.E. Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. Am. J. Hum. Genet., 2006, 79, 264-274. (Pubitemid 44141825)
27. Schmiegelow, K. Advances in individual prediction of metho trexate toxicity: A review. Br. J. Haematol., 2009, 146, 489-503.
28. de Beaumais, T.A.; Jacqz-Aigrain, E. Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children. Curr. Drug. Metab., 2012, 13, 822-834.
29. Salazar, J.; Altes, A.; del Rio, E.; Estella, J.; Rives, S.; Tasso, M.; Navajas, A.; Molina, J.; Villa, M.; Vivanco, J.L.; Torrent, M.; Baiget, M.; Badell, I. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmaco genomics J., 2012, 12, 379-385.
30. Lopez-Lopez, E.; Martin-Guerrero, I.; Ballesteros, J.; Garcia-Orad, A. A systematic review and meta-analysis of MTHFR polymor phisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J., 2012, doi: 10.1038/tpj.2012.44. [Epub ahead of print].
31. Spyridopoulou, K.P.; Dimou, N.L.; Hamodrakas, S.J.; Bagos, P.G. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: A meta-analysis. Pharmacogenet. Genomics, 2012, 22, 117-133.
32. Lopez-Lopez, E.; Martin-Guerrero, I.; Ballesteros, J.; Pinan, M.A.; Garcia-Miguel, P.; Navajas, A.; Garcia-Orad, A. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer, 2011, 57, 612-619.
33. Ramsey, L.B.; Bruun, G.H.; Yang, W.; Trevino, L.R.; Vattathil, S.; Scheet, P.; Cheng, C.; Rosner, G.L.; Giacomini, K.M.; Fan, Y.; Sparreboom, A.; Mikkelsen, T.S.; Corydon, T.J.; Pui, C.H.; Evans, W.E.; Relling, M.V. Rare versus common variants in pharmaco genetics: SLCO1B1 variation and methotrexate disposition. Genome Res., 2012, 22, 1-8.
34. Pui, C.H.; Campana, D.; Pei, D.; Bowman, W.P.; Sandlund, J.T.; Kaste, S.C.; Ribeiro, R.C.; Rubnitz, J.E.; Raimondi, S.C.; Onciu, M.; Coustan-Smith, E.; Kun, L.E.; Jeha, S.; Cheng, C.; Howard, S.C.; Simmons, V.; Bayles, A.; Metzger, M.L.; Boyett, J.M.; Leung, W.; Handgretinger, R.; Downing, J.R.; Evans, W.E.; Relling, M.V. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med., 2009, 360, 2730-2741.
35. Mikkelsen, T.S.; Sparreboom, A.; Cheng, C.; Zhou, Y.; Boyett, J.M.; Raimondi, S.C.; Panetta, J.C.; Bowman, W.P.; Sandlund, J.T.; Pui, C.H.; Relling, M.V.; Evans, W.E. Shortening infusion time for high-dose methotrexate alters antileukemic effects: A randomized prospective clinical trial. J. Clin. Oncol., 2011, 29, 1771-1778.
36. Nordeen, S.K.; Suh, B.J.; Kuhnel, B.; Hutchison, C.A., 3rd. Structural determinants of a glucocorticoid receptor recognition element. Mol. Endocrinol., 1990, 4, 1866-1873.
37. Kaspers, G.J.; Pieters, R.; Van Zantwijk, C.H.; Van Wering, E.R.; Van Der Does-Van Den Berg, A.; Veerman, A.J. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs. Blood, 1998, 92, 259-266. (Pubitemid 28303201)
38. Hongo, T.; Yajima, S.; Sakurai, M.; Horikoshi, Y.; Hanada, R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood, 1997, 89, 2959-2965. (Pubitemid 27172583)
39. Den Boer, M.L.; Harms, D.O.; Pieters, R.; Kazemier, K.M.; Gobel, U.; Korholz, D.; Graubner, U.; Haas, R.J.; Jorch, N.; Spaar, H.J.; Kaspers, G.J.; Kamps, W.A.; Van der Does-Van den Berg, A.; Van Wering, E.R.; Veerman, A.J.; Janka-Schaub, G.E. Patient stratification based on prednisolone-vincristine- asparaginase resistance profiles in children with acute lymphoblastic leukemia. J. Clin. Oncol., 2003, 21, 3262-3268. (Pubitemid 46606259)
40. De Iudicibus, S.; Franca, R.; Martelossi, S.; Ventura, A.; Decorti, G. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J. Gastroenterol., 2011, 17, 1095-1108.
41. Franca, R.; Rebora, P.; Basso, G.; Biondi, A.; Cazzaniga, G.; Crovella, S.; Decorti, G.; Fagioli, F.; Giarin, E.; Locatelli, F.; Poggi, V.; Valsecchi, M.G.; Rabusin, M. Glutathione S-transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: A novel study design in a large Italian AIEOP cohort. Pharmacogenomics, 2012, 16, 1905-1916.
42. Rocha, J.C.; Cheng, C.; Liu, W.; Kishi, S.; Das, S.; Cook, E.H.; Sandlund, J.T.; Rubnitz, J.; Ribeiro, R.; Campana, D.; Pui, C.H.; Evans, W.E.; Relling, M.V. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood, 2005, 105, 4752-4758. (Pubitemid 40807300)
43. Relling, M.V.; Yang, W.; Das, S.; Cook, E.H.; Rosner, G.L.; Neel, M.; Howard, S.; Ribeiro, R.; Sandlund, J.T.; Pui, C.H.; Kaste, S.C. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J. Clin. Oncol., 2004, 22, 3930-3936. (Pubitemid 41079875)
44. Kawedia, J.D.; Kaste, S.C.; Pei, D.; Panetta, J.C.; Cai, X.; Cheng, C.; Neale, G.; Howard, S.C.; Evans, W.E.; Pui, C.H.; Relling, M.V. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2011, 117, 2340-2347.
45. Bottini, N.; MacMurray, J.; Peters, W.; Rostamkhani, M.; Comings, D.E. Association of the acid phosphatase (ACP1) gene with triglyceride levels in obese women. Mol. Genet. Metab., 2002, 77, 226-229. (Pubitemid 35333827)
46. Zambuzzi, W.F.; Granjeiro, J.M.; Parikh, K.; Yuvaraj, S.; Peppelenbosch, M.P.; Ferreira, C.V. Modulation of Src activity by low molecular weight protein tyrosine phosphatase during osteoblast differentiation. Cell Physiol. Biochem., 2008, 22, 497-506.
47. French, D.; Hamilton, L.H.; Mattano, L.A., Jr.; Sather, H.N.; Devidas, M.; Nachman, J.B.; Relling, M.V. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood, 2008, 111, 4496-4499.
48. Bond, J.; Adams, S.; Richards, S.; Vora, A.; Mitchell, C.; Goulden, N. Polymorphism in the PAI-1 (SERPINE1) gene and the risk of osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2011, 118, 2632-2633.
49. Kamdem, L.K.; Hamilton, L.; Cheng, C.; Liu, W.; Yang, W.; Johnson, J.A.; Pui, C.H.; Relling, M.V. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet. Genomics, 2008, 18, 507-514. (Pubitemid 351769918)
50. Dennison, J.B.; Kulanthaivel, P.; Barbuch, R.J.; Renbarger, J.L.; Ehlhardt, W.J.; Hall, S.D. Selective metabolism of vincristine in vitro by CYP3A5. Drug. Metab. Dispos., 2006, 34, 1317-1327. (Pubitemid 44079872)
51. Dennison, J.B.; Jones, D.R.; Renbarger, J.L.; Hall, S.D. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J. Pharmacol. Exp. Ther., 2007, 321, 553-563. (Pubitemid 46628594)
52. Xie, H.G.; Wood, A.J.; Kim, R.B.; Stein, C.M.; Wilkinson, G.R. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics, 2004, 5, 243-272. (Pubitemid 38499965)
53. Hustert, E.; Haberl, M.; Burk, O.; Wolbold, R.; He, Y.Q.; Klein, K.; Nuessler, A.C.; Neuhaus, P.; Klattig, J.; Eiselt, R.; Koch, I.; Zibat, A.; Brockmoller, J.; Halpert, J.R.; Zanger, U.M.; Wojnowski, L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics, 2001, 11, 773-779. (Pubitemid 33151512)
54. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P.B.; Daly, A.; Wrighton, S.A.; Hall, S.D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M.S.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 2001, 27, 383-391. (Pubitemid 32268418)
55. Lamba, J.K.; Lin, Y.S.; Schuetz, E.G.; Thummel, K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug. Deliv. Rev., 2002, 54, 1271-1294. (Pubitemid 35284253)
56. Groninger, E.; Meeuwsen-de Boar, T.; Koopmans, P.; Uges, D.; Sluiter, W.; Veerman, A.; Kamps, W.; de Graaf, S. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr. Res., 2002, 52, 113-118. (Pubitemid 34665960)
57. Egbelakin, A.; Ferguson, M.J.; MacGill, E.A.; Lehmann, A.S.; Topletz, A.R.; Quinney, S.K.; Li, L.; McCammack, K.C.; Hall, S.D.; Renbarger, J.L. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr. Blood Cancer, 2011, 56, 361-367.
58. Borst, L.; Wallerek, S.; Dalhoff, K.; Rasmussen, K.K.; Wesenberg, F.; Wehner, P.S.; Schmiegelow, K. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia. Eur. J. Haematol., 2011, 86, 477-483.
59. Aplenc, R.; Glatfelter, W.; Han, P.; Rappaport, E.; La, M.; Cnaan, A.; Blackwood, M.A.; Lange, B.; Rebbeck, T. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br. J. Haematol., 2003, 122, 240-244. (Pubitemid 36859609)
60. Lamba, J.; Hebert, J.M.; Schuetz, E.G.; Klein, T.E.; Altman, R.B. PharmGKB summary: Very important pharmacogene information for CYP3A5. Pharmacogenet. Genomics, 2012, 22, 555-558.
61. Thorn, C.F.; Ji, Y.; Weinshilboum, R.M.; Altman, R.B.; Klein, T.E. PharmGKB summary: Very important pharmacogene information for GSTT1. Pharmacogenet. Genomics, 2012, 22, 646-651.
62. Hodges, L.M.; Markova, S.M.; Chinn, L.W.; Gow, J.M.; Kroetz, D.L.; Klein, T.E.; Altman, R.B. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet. Genomics, 2011, 21, 152-161.
63. Wertz, I.E.; Kusam, S.; Lam, C.; Okamoto, T.; Sandoval, W.; Anderson, D.J.; Helgason, E.; Ernst, J.A.; Eby, M.; Liu, J.; Belmont, L.D.; Kaminker, J.S.; O'Rourke, K.M.; Pujara, K.; Kohli, P.B.; Johnson, A.R.; Chiu, M.L.; Lill, J.R.; Jackson, P.K.; Fairbrother, W.J.; Seshagiri, S.; Ludlam, M.J.; Leong, K.G.; Dueber, E.C.; Maecker, H.; Huang, D.C.; Dixit, V.M. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature, 2011, 471, 110-114.
64. Wang, Z.; Fukushima, H.; Gao, D.; Inuzuka, H.; Wan, L.; Lau, A.W.; Liu, P.; Wei, W. The two faces of FBW7 in cancer drug resistance. Bioessays, 2011, 33, 851-859.
65. Inuzuka, H.; Shaik, S.; Onoyama, I.; Gao, D.; Tseng, A.; Maser, R.S.; Zhai, B.; Wan, L.; Gutierrez, A.; Lau, A.W.; Xiao, Y.; Christie, A.L.; Aster, J.; Settleman, J.; Gygi, S.P.; Kung, A.L.; Look, T.; Nakayama, K.I.; DePinho, R.A.; Wei, W. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature, 2011, 471, 104-109.
66. Maser, R.S.; Choudhury, B.; Campbell, P.J.; Feng, B.; Wong, K.K.; Protopopov, A.; O'Neil, J.; Gutierrez, A.; Ivanova, E.; Perna, I.; Lin, E.; Mani, V.; Jiang, S.; McNamara, K.; Zaghlul, S.; Edkins, S.; Stevens, C.; Brennan, C.; Martin, E.S.; Wiedemeyer, R.; Kabbarah, O.; Nogueira, C.; Histen, G.; Aster, J.; Mansour, M.; Duke, V.; Foroni, L.; Fielding, A.K.; Goldstone, A.H.; Rowe, J.M.; Wang, Y.A.; Look, A.T.; Stratton, M.R.; Chin, L.; Futreal, P.A.; DePinho, R.A. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature, 2007, 447, 966-971. (Pubitemid 46975753)
67. O'Neil, J.; Grim, J.; Strack, P.; Rao, S.; Tibbitts, D.; Winter, C.; Hardwick, J.; Welcker, M.; Meijerink, J.P.; Pieters, R.; Draetta, G.; Sears, R.; Clurman, B.E.; Look, A.T. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med., 2007, 204, 1813-1824. (Pubitemid 47236319)
68. Thompson, B.J.; Buonamici, S.; Sulis, M.L.; Palomero, T.; Vilimas, T.; Basso, G.; Ferrando, A.; Aifantis, I. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med., 2007, 204, 1825-1835. (Pubitemid 47236320)
69. Kox, C.; Zimmermann, M.; Stanulla, M.; Leible, S.; Schrappe, M.; Ludwig, W.D.; Koehler, R.; Tolle, G.; Bandapalli, O.R.; Breit, S.; Muckenthaler, M.U.; Kulozik, A.E. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia, 2010, 24, 2005-2013.
70. Haskell, C.M.; Canellos, G.P. l-asparaginase resistance in human leukemia-asparagine synthetase. Biochem. Pharmacol., 1969, 18, 2578-2580.
71. Horowitz, B.; Madras, B.K.; Meister, A.; Old, L.J.; Boyes, E.A.; Stockert, E. Asparagine synthetase activity of mouse leukemias. Science, 1968, 160, 533-535.
72. Kiriyama, Y.; Kubota, M.; Takimoto, T.; Kitoh, T.; Tanizawa, A.; Akiyama, Y.; Mikawa, H. Biochemical characterization of U937 cells resistant to L-asparaginase: The role of asparagine synthetase. Leukemia, 1989, 3, 294-297. (Pubitemid 19092763)
73. Hutson, R.G.; Kitoh, T.; Moraga Amador, D.A.; Cosic, S.; Schuster, S.M.; Kilberg, M.S. Amino acid control of asparagine synthetase: Relation to asparaginase resistance in human leukemia cells. Am. J. Physiol., 1997, 272, C1691-1699.
74. den Boer, M.L.; Pieters, R.; Kazemier, K.M.; Rottier, M.M.; Zwaan, C.M.; Kaspers, G.J.; Janka-Schaub, G.; Henze, G.; Creutzig, U.; Scheper, R.J.; Veerman, A.J. Relationship between major vault protein/lung resistance protein, multidrug resistanceassociated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood, 1998, 91, 2092-2098. (Pubitemid 28185513)
75. Aslanian, A.M.; Fletcher, B.S.; Kilberg, M.S. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem. J., 2001, 357, 321-328. (Pubitemid 32642933)
76. Aslanian, A.M.; Kilberg, M.S. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginaseresistant MOLT-4 human leukaemia cells. Biochem. J., 2001, 358, 59-67. (Pubitemid 32778098)
77. Krejci, O.; Starkova, J.; Otova, B.; Madzo, J.; Kalinova, M.; Hrusak, O.; Trka, J. Upregulation of asparagine synthetase fails to avert cell cycle arrest induced by L-asparaginase in TEL/AML1-positive leukaemic cells. Leukemia, 2004, 18, 434-441. (Pubitemid 38425856)
78. Stams, W.A.; den Boer, M.L.; Holleman, A.; Appel, I.M.; Beverloo, H.B.; van Wering, E.R.; Janka-Schaub, G.E.; Evans, W.E.; Pieters, R. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TELAML1-positive pediatric acute lymphoblastic leukemia. Blood, 2005, 105, 4223-4225. (Pubitemid 40720766)
79. Stams, W.A.; den Boer, M.L.; Beverloo, H.B.; Meijerink, J.P.; Stigter, R.L.; van Wering, E.R.; Janka-Schaub, G.E.; Slater, R.; Pieters, R. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood, 2003, 101, 2743-2747. (Pubitemid 36857638)
80. Panetta, J.C.; Gajjar, A.; Hijiya, N.; Hak, L.J.; Cheng, C.; Liu, W.; Pui, C.H.; Relling, M.V. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin. Pharmacol. Ther., 2009, 86, 651-658.
81. Kearney, S.L.; Dahlberg, S.E.; Levy, D.E.; Voss, S.D.; Sallan, S.E.; Silverman, L.B. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr. Blood Cancer, 2009, 53, 162-167.
82. Pieters, R.; Hunger, S.P.; Boos, J.; Rizzari, C.; Silverman, L.; Baruchel, A.; Goekbuget, N.; Schrappe, M.; Pui, C.H. Lasparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer, 2011, 117, 238-249.
83. Kawedia, J.D.; Liu, C.; Pei, D.; Cheng, C.; Fernandez, C.A.; Howard, S.C.; Campana, D.; Panetta, J.C.; Bowman, W.P.; Evans, W.E.; Pui, C.H.; Relling, M.V. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood, 2012, 119, 1658-1664.
84. Kanehisa, M.; Goto, S.; Sato, Y.; Furumichi, M.; Tanabe, M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res., 2012, 40, D109-114.
85. Kanehisa Alanine, aspartate and glutamate metabolism -Reference pathway http://www.genome.jp/keggbin/show-pathway?map00250 (2013-01-03),
86. Chen, S.H.; Yang, W.; Fan, Y.; Stocco, G.; Crews, K.R.; Yang, J.J.; Paugh, S.W.; Pui, C.H.; Evans, W.E.; Relling, M.V. A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia, 2011, 25, 66-74.
87. Estes, D.A.; Lovato, D.M.; Khawaja, H.M.; Winter, S.S.; Larson, R.S. Genetic alterations determine chemotherapy resistance in childhood T-ALL: Modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br. J. Haematol., 2007, 139, 20-30. (Pubitemid 47389934)
88. Rousseau, J.; Gagne, V.; Labuda, M.; Beaubois, C.; Sinnett, D.; Laverdiere, C.; Moghrabi, A.; Sallan, S.E.; Silverman, L.B.; Neuberg, D.; Kutok, J.L.; Krajinovic, M. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood, 2011, 118, 5883-5890.
89. Al Sarraj, J.; Vinson, C.; Thiel, G. Regulation of asparagine synthetase gene transcription by the basic region leucine zipper transcription factors ATF5 and CHOP. Biol. Chem., 2005, 386, 873-879. (Pubitemid 41448143)
90. Richards, N.G.; Kilberg, M.S. Asparagine synthetase chemo therapy. Annu. Rev. Biochem., 2006, 75, 629-654.
91. Franco, R.; Pacheco, R.; Lluis, C.; Ahern, G.P.; O'Connell, P.J. The emergence of neurotransmitters as immune modulators. Trends Immunol., 2007, 28, 400-407. (Pubitemid 47385376)
92. Pacheco, R.; Gallart, T.; Lluis, C.; Franco, R. Role of glutamate on T-cell mediated immunity. J. Neuroimmunol., 2007, 185, 9-19. (Pubitemid 46497434)
93. Huffman, D.H.; Benjamin, R.S.; Bachur, N.R. Daunorubicin metabolism in acute nonlymphocytic leukemia. Clin. Pharmacol. Ther., 1972, 13, 895-905.
94. Dessypris, E.N.; Brenner, D.E.; Hande, K.R. Toxicity of doxorubicin metabolites to human marrow erythroid and myeloid progenitors in vitro. Cancer Treat. Rep., 1986, 70, 487-490. (Pubitemid 16116453)
95. Schott, B.; Robert, J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem. Pharmacol., 1989, 38, 4069-4074. (Pubitemid 20008745)
96. Olson, R.D.; Mushlin, P.S.; Brenner, D.E.; Fleischer, S.; Cusack, B.J.; Chang, B.K.; Boucek, R.J., Jr. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl. Acad. Sci. U. S. A., 1988, 85, 3585-3589.
97. Visscher, H.; Ross, C.J.; Rassekh, S.R.; Barhdadi, A.; Dube, M.P.; Al-Saloos, H.; Sandor, G.S.; Caron, H.N.; van Dalen, E.C.; Kremer, L.C.; van der Pal, H.J.; Brown, A.M.; Rogers, P.C.; Phillips, M.S.; Rieder, M.J.; Carleton, B.C.; Hayden, M.R. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol., 2012, 30, 1422-1428.
98. Zeller, T.; Wild, P.; Szymczak, S.; Rotival, M.; Schillert, A.; Castagne, R.; Maouche, S.; Germain, M.; Lackner, K.; Rossmann, H.; Eleftheriadis, M.; Sinning, C.R.; Schnabel, R.B.; Lubos, E.; Mennerich, D.; Rust, W.; Perret, C.; Proust, C.; Nicaud, V.; Loscalzo, J.; Hubner, N.; Tregouet, D.; Munzel, T.; Ziegler, A.; Tiret, L.; Blankenberg, S.; Cambien, F. Genetics and beyond-the transcriptome of human monocytes and disease susceptibility. PLoS One, 2010, 5, e10693.
99. Nagasawa, K.; Nagai, K.; Ohnishi, N.; Yokoyama, T.; Fujimoto, S. Contribution of specific transport systems to anthracycline transport in tumor and normal cells. Curr. Drug Metab., 2001, 2, 355-366. (Pubitemid 33133980)
100. Wiley, J.S.; Jones, S.P.; Sawyer, W.H.; Paterson, A.R. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J. Clin. Invest., 1982, 69, 479-489. (Pubitemid 12177627)
101. Kessel, D.; Hall, T.C.; Wodinsky, I. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science, 1967, 156, 1240-1241.
102. Kufe, D.W.; Major, P.P.; Egan, E.M.; Beardsley, G.P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem., 1980, 255, 8997-8900.
103. Kufe, D.W.; Munroe, D.; Herrick, D.; Egan, E.; Spriggs, D. Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol. Pharmacol., 1984, 26, 128-134. (Pubitemid 14035234)
104. Lamba, J.K. Genetic factors influencing cytarabine therapy. Pharmacogenomics, 2009, 10, 1657-1674.
105. Galmarini, C.M.; Thomas, X.; Calvo, F.; Rousselot, P.; Rabilloud, M.; El Jaffari, A.; Cros, E.; Dumontet, C. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol., 2002, 117, 860-868. (Pubitemid 34639247)
106. Stam, R.W.; den Boer, M.L.; Meijerink, J.P.; Ebus, M.E.; Peters, G.J.; Noordhuis, P.; Janka-Schaub, G.E.; Armstrong, S.A.; Korsmeyer, S.J.; Pieters, R. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL generearranged infant acute lymphoblastic leukemia. Blood, 2003, 101, 1270-1276. (Pubitemid 36182495)
107. Galmarini, C.M.; Cros, E.; Thomas, X.; Jordheim, L.; Dumontet, C. The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica, 2005, 90, 1699-1701. (Pubitemid 41814998)
108. Galmarini, C.M.; Thomas, X.; Calvo, F.; Rousselot, P.; El Jafaari, A.; Cros, E.; Dumontet, C. Potential mechanisms of resistance to cytarabine in AML patients. Leuk. Res., 2002, 26, 621-629. (Pubitemid 34465699)
109. Jahns-Streubel, G.; Reuter, C.; Auf der Landwehr, U.; Unterhalt, M.; Schleyer, E.; Wormann, B.; Buchner, T.; Hiddemann, W. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood, 1997, 90, 1968-1976. (Pubitemid 27377308)
110. Schroder, J.K.; Kirch, C.; Seeber, S.; Schutte, J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br. J. Haematol., 1998, 103, 1096-1103. (Pubitemid 29012650)
111. Lamba, J.K.; Crews, K.; Pounds, S.; Schuetz, E.G.; Gresham, J.; Gandhi, V.; Plunkett, W.; Rubnitz, J.; Ribeiro, R. Pharmaco genetics of deoxycytidine kinase: Identification and characteri zation of novel genetic variants. J. Pharmacol. Exp. Ther., 2007, 323, 935-945. (Pubitemid 350146062)
112. Bhatla, D.; Gerbing, R.B.; Alonzo, T.A.; Conner, H.; Ross, J.A.; Meshinchi, S.; Zhai, X.; Zamzow, T.; Mehta, P.A.; Geiger, H.; Perentesis, J.; Davies, S.M. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br. J. Haematol., 2009, 144, 388-394.
113. Hartford, C.M.; Duan, S.; Delaney, S.M.; Mi, S.; Kistner, E.O.; Lamba, J.K.; Huang, R.S.; Dolan, M.E. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood, 2009, 113, 2145-2153.
114. Lamba, J.K.; Crews, K.R.; Pounds, S.B.; Cao, X.; Gandhi, V.; Plunkett, W.; Razzouk, B.I.; Lamba, V.; Baker, S.D.; Raimondi, S.C.; Campana, D.; Pui, C.H.; Downing, J.R.; Rubnitz, J.E.; Ribeiro, R.C. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics, 2011, 12, 327-339.
115. Hu, L.; Zhuo, W.; He, Y.J.; Zhou, H.H.; Fan, L. Pharmacogenetics of P450 oxidoreductase: Implications in drug metabolism and therapy. Pharmacogenet. Genomics, 2012, 22, 812-819.
116. Whirl-Carrillo, M.; McDonagh, E.M.; Hebert, J.M.; Gong, L.; Sangkuhl, K.; Thorn, C.F.; Altman, R.B.; Klein, T.E. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther., 2012, 92, 414-417.
117. Thorn, C.F.; Lamba, J.K.; Lamba, V.; Klein, T.E.; Altman, R.B. PharmGKB summary: Very important pharmacogene information for CYP2B6. Pharmacogenet. Genomics, 2010, 20, 520-523.
118. Porter, T.D.; Coon, M.J. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J. Biol. Chem., 1991, 266, 13469-13472. (Pubitemid 21907368)
119. Chen, L.; Yu, L.J.; Waxman, D.J. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res., 1997, 57, 4830-4837. (Pubitemid 27468991)
120. Klein, T.E.; Chang, J.T.; Cho, M.K.; Easton, K.L.; Fergerson, R.; Hewett, M.; Lin, Z.; Liu, Y.; Liu, S.; Oliver, D.E.; Rubin, D.L.; Shafa, F.; Stuart, J.M.; Altman, R.B. Integrating genotype and phenotype information: An overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J., 2001, 1, 167-170. (Pubitemid 33756654)
121. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Druker, B.J.; Lydon, N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 1996, 56, 100-104.
122. Biondi, A.; Schrappe, M.; De Lorenzo, P.; Castor, A.; Lucchini, G.; Gandemer, V.; Pieters, R.; Stary, J.; Escherich, G.; Campbell, M.; Li, C.K.; Vora, A.; Arico, M.; Rottgers, S.; Saha, V.; Valsecchi, M.G. Imatinib after induction for treatment of children and adolescents with Philadelphia- chromosome-positive acute lympho blastic leukaemia (EsPhALL): A randomised, open-label, intergroup study. Lancet Oncol., 2012, 13, 936-945.
123. Petain, A.; Kattygnarath, D.; Azard, J.; Chatelut, E.; Delbaldo, C.; Geoerger, B.; Barrois, M.; Seronie-Vivien, S.; LeCesne, A.; Vassal, G. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin. Cancer Res., 2008, 14, 7102-7109.
124. Peng, B.; Lloyd, P.; Schran, H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet., 2005, 44, 879-894. (Pubitemid 41252840)
125. Deininger, M.; Buchdunger, E.; Druker, B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 2005, 105, 2640-2653. (Pubitemid 40446252)
126. Savonarola, A.; Palmirotta, R.; Guadagni, F.; Silvestris, F. Pharmacogenetics and pharmacogenomics: Role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics J., 2012, 12, 277-286.
127. Dulucq, S.; Krajinovic, M. The pharmacogenetics of imanitib. Genome Med., 2010, 2, 85.
128. Angelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.P.; White, D.L.; Radich, J.; Kim, D.W.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica, 2012, 98, 193-200.
129. Gandhi, V.; Plunkett, W. Cellular and clinical pharmacology of fludarabine. Clin. Pharmacokinet., 2002, 41, 93-103. (Pubitemid 34264036)
130. Rivero, A.; Rapado, I.; Tomas, J.F.; Montalban, C.; de Ona, R.; Paz-Carreira, J.; Canales, M.; Martinez, R.; Sanchez-Godoy, P.; de Sevilla, A.F.; de la Serna, J.; Martinez-Lopez, J. Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma. Leuk. Res., 2011, 35, 431-437.
131. Quarello, P.; Berger, M.; Rivetti, E.; Galletto, C.; Masetti, R.; Manicone, R.; Barisone, E.; Pession, A.; Fagioli, F. FLAGliposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients. J. Pediatr. Hematol. Oncol., 2012, 34, 208-216.
132. Lotfi, K.; Mansson, E.; Spasokoukotskaja, T.; Pettersson, B.; Liliemark, J.; Peterson, C.; Eriksson, S.; Albertioni, F. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin. Cancer Res., 1999, 5, 2438-2444. (Pubitemid 29437325)
133. Genini, D.; Adachi, S.; Chao, Q.; Rose, D.W.; Carrera, C.J.; Cottam, H.B.; Carson, D.A.; Leoni, L.M. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood, 2000, 96, 3537-3543.
134. Bonate, P.L.; Arthaud, L.; Cantrell, W.R., Jr.; Stephenson, K.; Secrist, J.A., 3rd; Weitman, S. Discovery and development of clofarabine: A nucleoside analogue for treating cancer. Nat. Rev. Drug Discov., 2006, 5, 855-863. (Pubitemid 44480539)
135. Hijiva, N.; Barry, E; Arceci, R. Clofarabine in pediatric acute leukemia: Current findings and issues. Pediatric Blood Cancer, 2012, 59, 417-422.
136. Zhang, Y.; Shahriar, M.; Zhang, J.; Ahmed, S.U.; Lim, S.H. Clofarabine induces hypomethylation of DNA and expression of Cancer-Testis antigens. Leuk. Res., 2009, 33, 1678-1683.
137. Evans, W.E.; Relling, M.V. Moving towards individualized medicine with pharmacogenomics. Nature, 2004, 429, 464-468. (Pubitemid 38715141)
138. Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 variants and statininduced myopathy-A genomewide study. N. Engl. J. Med., 2008, 359, 789-799.
139. Yang, J.J.; Cheng, C.; Yang, W.; Pei, D.; Cao, X.; Fan, Y.; Pounds, S.B.; Neale, G.; Trevino, L.R.; French, D.; Campana, D.; Downing, J.R.; Evans, W.E.; Pui, C.H.; Devidas, M.; Bowman, W.P.; Camitta, B.M.; Willman, C.L.; Davies, S.M.; Borowitz, M.J.; Carroll, W.L.; Hunger, S.P.; Relling, M.V. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA, 2009, 301, 393-403.
140. Yang, J.J.; Cheng, C.; Devidas, M.; Cao, X.; Campana, D.; Yang, W.; Fan, Y.; Neale, G.; Cox, N.; Scheet, P.; Borowitz, M.J.; Winick, N.J.; Martin, P.L.; Bowman, P.; Camitta, B.; Reaman, G.H.; Carroll, W.L.; Willman, C.L.; Hunger, S.P.; Evans, W.E.; Pui, C.H.; Loh, M.; Relling, M.V. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood, 2012, 120, 4197-4204.
141. Pui, C.H.; Mullighan, C.G.; Evans, W.E.; Relling, M.V. Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood, 2012, 120, 1165-1174.
142. Mody, R.; Li, S.; Dover, D.C.; Sallan, S.; Leisenring, W.; Oeffinger, K.C.; Yasui, Y.; Robison, L.L.; Neglia, J.P. Twentyfive-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Blood, 2008, 111, 5515-5523.
143. Pui, C.H.; Cheng, C.; Leung, W.; Rai, S.N.; Rivera, G.K.; Sandlund, J.T.; Ribeiro, R.C.; Relling, M.V.; Kun, L.E.; Evans, W.E.; Hudson, M.M. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N. Engl. J. Med., 2003, 349, 640-649. (Pubitemid 36975996)